NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









GlycoTherapeutics

GlycoTherapeutics

Private
NijmegenHealthcare & Life Scienceshttps://glycotherapeutics.eu/

Last Round

Grant

Jul 10, 2025

Total Funding Raised

$2.37M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

GlycoTherapeutics is a biotechnology company that develops anticancer drugs targeting glycans to overcome efficacy limitations in cancer immunotherapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

glycobiologycancer immunotherapyimmuno-oncologydrug discoveryimmune evasiononcology therapeuticspreclinical biotechglycan-targeted therapybiotech startupfucosesialic acidpharma licensingdrug developmentbiologicssugar-based drugs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GlycoTherapeutics Comparables

Compare GlycoTherapeutics with similar companies based on industry and business-model similarity.

GlycoTherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Valora Therapeutics Inc.
84%
Tacalyx
83%
Adaptam Therapeutics
81%

GlycoTherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 10, 2025
GrantApr 26, 2023
GrantFeb 14, 2023
GrantJan 1, 2022

Key People

Founding team and executive leadership

Johan Pijnenborg

CEO Co-Founder

Founding Team

GlycoTherapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 17, 2026

    Grew 200% QoQ, from 2 to 6 employees.

  • Jul 10, 2025

    Received grant funding to support operations.

GlycoTherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GlycoTherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GlycoTherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNijmegen
Employee Range6
Year Founded2022
Last FundingJul 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.